HMGB1 and myeloid sarcoma: HMGB1 neutralization strategy in a diverse range of HMGB1-mediated pathologies such as Epilepsy (Fu et al., 2017), MS (Robinson et al., 2013), Traumatic brain injury (TBI) (Okuma et al., 2012) and cognitive decline (Hei et al., 2018; Okuma et al., 2019) has been well reported.